QuidelOrtho Corporation (NASDAQ: QDEL) recently received a “Hold” rating from Tycho Peterson of Jefferies, as of May 7, 2026. This rating comes amid a backdrop of fluctuating stock performance and disappointing earnings figures that warrant caution for prospective investors. At the recent price of $10.77, this recommendation casts a spotlight on the company’s current challenges while hinting at potential upside based on a price target set at $12.50.
Recent Price Action
In the wake of Jefferies’ rating change, QDEL shares have experienced notable movement. Priced at $10.77, the stock has seen an uptick of 3.90%, or $0.43, in its last trading session, though awareness of broader market volatility is essential. The stock has a market cap of approximately $763.7 million and a beta of 0.744, indicating it tends to be less volatile than the overall market. Over the past 52 weeks, QDEL has encountered significant challenges, with a high point of $16.41 but plummeting to lows of $10.77. Recent trading volume has averaged 2.5 million, while current trading showed 592,235 shares exchange hands, suggesting a degree of investor caution rather than bullish enthusiasm.
Short- and Long-Term Performance
Analyzing QDEL’s performance over various timeframes reveals a mixed bag. In the last month, shares are up by 11.36%, reflecting some recovery in sentiment following prior downturns. A more robust quarterly performance of 16.35% offers a positive glimpse into the company’s short-term resilience, although the one-year performance remains troubling, with a decline of 21.85%—a stark contrast that raises flags regarding long-term viability. Weekly volatility stands at 6.24%, while monthly volatility, at 4.91%, highlights some investor uncertainty. This volatility, juxtaposed against an average 10-day volume close to 2.8 million, points to a market grappling with direction as it weighs future prospects for the stock.
Earnings / Financials
The latest earnings data from QuidelOrtho paints a grim picture, with the company reporting an actual EPS of -$0.04 compared to an estimated EPS of $0.37, resulting in a staggering surprise factor of -110.81%. This sharp miss follows a more favorable EPS figure of $0.46 reported in February, which had itself exceeded estimates by a modest margin. Such volatility in earnings expectations is concerning and suggests the company is struggling to establish predictability, a trait often unfavorable in investment circles.
Analyst / Consensus View
The consensus among analysts remains notably cautious. Only four ratings have been issued, all classified as “Holds,” reflecting a lack of bullish sentiment in the market. Despite having a suggested price target of $12.50—equal to the recent price—this indicates only a modest upside potential. The average price target across the board sits higher at $18.125, with a ceiling of $30 from the most optimistic projections. However, the absence of buy ratings suggests a pervasive wariness about QDEL’s immediate potential or ongoing challenges in execution.
Stock Grading or Fundamental View
QuidelOrtho holds an ST Score of 46, derived from in-depth analysis across financial and market health metrics. This score positions the company in a middle ground, indicating challenges in some operational areas while also suggesting that there are elements worth monitoring for recovery prospects. Investors looking for fundamental strength may find the current grading as more indicative of caution rather than robust opportunity.
Conclusion
For investors eyeing QuidelOrtho Corporation, it is essential to approach the stock with a balanced perspective. The recent hold rating signals that it may appeal to those with a patient, defensive investment strategy rather than aggressive growth pursuits. While the stock’s recent recovery and potential upside can be enticing, the significant earnings miss and lack of enthusiastic analyst support introduce considerable risks. Long-term investors may need to focus on await clearer performance signals before committing capital, as the current environment suggests a ‘wait-and-see’ approach could be prudent.